X0206 3 2017-12-07 0 0001714899 Denali Therapeutics Inc. DNLI 0001605598 ARCH Venture Fund VIII, L.P. C/O ARCH VENTURE PARTNERS VIII, LLC 8755 W. HIGGINS ROAD, SUITE 1025 CHICAGO IL 60631 0 0 1 0 0001616165 ARCH Venture Partners VIII, LLC C/O ARCH VENTURE PARTNERS 8755 W. HIGGINS ROAD, SUITE 1025 CHICAGO IL 60631 0 0 1 0 0001616176 ARCH Venture Partners VIII, L.P. C/O ARCH VENTURE PARTNERS VIII, LLC 8755 W. HIGGINS ROAD, SUITE 1025 CHICAGO IL 60631 0 0 1 0 0001219039 CRANDELL KEITH C/O ARCH VENTURE PARTNERS VIII, LLC 8755 W. HIGGINS ROAD, SUITE 1025 CHICAGO IL 60631 0 0 1 0 0001219043 BYBEE CLINTON C/O ARCH VENTURE PARTNERS VIII, LLC 8755 W. HIGGINS ROAD, SUITE 1025 CHICAGO IL 60631 0 0 1 0 Common Stock 312500 D Series A-1 Preferred Stock Common Stock 10068749 D Series A-2 Preferred Stock Common Stock 375000 D Series B-1 Preferred Stock Common Stock 312500 D The shares are directly held by ARCH Venture Fund VIII, L.P. ("ARCH VIII"). ARCH Venture Partners VIII, L.P. (the "GPLP"), as the sole general partner of ARCH VIII, may be deemed to beneficially own certain of the shares held by ARCH VIII. ARCH Venture Partners VIII, LLC ("GPLLC"), as the sole general partner of GPLP, may be deemed to beneficially own the shares held by ARCH VIII. The GPLP and GPLLC disclaim beneficial ownership of such shares except to the extent of any pecuniary interest therein. Keith Crandell and Clinton Bybee, as managing directors of GPLLC, may be deemed to beneficially own the shares held by ARCH VIII. Messrs. Crandell and Bybee disclaim beneficial ownership of such shares except to the extent of any pecuniary interest therein. The Series A-1 Preferred Stock shall automatically convert into shares of Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and has no expiration date. The Series A-2 Preferred Stock shall automatically convert into shares of Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and has no expiration date. The Series B-1 Preferred Stock shall automatically convert into shares of Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and has no expiration date. ARCH Venture Partners VIII, LLC By: /s/ Mark McDonnell, Attorney-in-Fact 2017-12-07 ARCH Venture Fund VIII, L.P. By: ARCH Venture Partners VIII, L.P. By: /s/ Mark McDonnell, Attorney-in-Fact 2017-12-07 ARCH Venture Partners VIII, L.P. By: ARCH Venture Partners VIII, LLC By: /s/ Mark McDonnell, Attorney-in-Fact 2017-12-07 /s/ Mark McDonnell, as Attorney-in-Fact for Keith Crandell 2017-12-07 /s/ Mark McDonnell, as Attorney-in-Fact for Clinton Bybee 2017-12-07